WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience
QUICK SEARCH:   [advanced]


     
-


HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (109)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Runz, H.
Right arrow Articles by Hartmann, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Runz, H.
Right arrow Articles by Hartmann, T.

 Previous Article  |  Next Article 

The Journal of Neuroscience, March 1, 2002, 22(5):1679-1689

Inhibition of Intracellular Cholesterol Transport Alters Presenilin Localization and Amyloid Precursor Protein Processing in Neuronal Cells

Heiko Runz1, 2, Jens Rietdorf2, Inge Tomic1, Marina de Bernard3, Konrad Beyreuther1, Rainer Pepperkok2, and Tobias Hartmann1

1 Center for Molecular Biology, University of Heidelberg, 69120 Heidelberg, Germany, 2 European Molecular Biology Laboratory, 69117 Heidelberg, Germany, and 3 Department of Biomedical Science, University of Padua, 35121 Padua, Italy


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Generation of amyloid-beta (Abeta ) from the amyloid precursor protein (APP) requires proteolytic cleavage by two proteases, beta - and gamma -secretase. Several lines of evidence suggest a role for cholesterol on secretase activities, although the responsible cellular mechanisms remain unclear. Here we show that alterations in cholesterol transport from late endocytic organelles to the endoplasmic reticulum have important consequences for both APP processing and the localization of gamma -secretase-associated presenilins (PS). Exposure of neuronal cells to cholesterol transport-inhibiting agents resulted in a marked decrease in beta -cleavage of full-length APP. In contrast, gamma -secretase activity on APP C-terminal fragments was enhanced, increasing the production of both Abeta 40 and Abeta 42. Remarkably, retention of cholesterol in endosomal/lysosomal compartments induced PS1 and PS2 to accumulate in Rab7-positive vesicular organelles implicated in cholesterol sorting. Accumulation of PS in vesicular compartments was prominent in both Chinese hamster ovary cells deficient in Niemann-Pick C1 protein as well as in neuronal cells exposed to the cholesterol transport-inhibiting agent U18666A. Because Abeta 42 also localized to PS1-containing vesicular compartments, organelles involved in cholesterol transport might represent an important site for gamma -secretase activity. Our results suggest that the subcellular distribution of cholesterol may be an important factor in how cholesterol alters Abeta production and the risk of Alzheimer's disease.

Key words: presenilin; cholesterol; NPC1; APP processing; Rab7; ACAT; amyloid-beta


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Although its primary function in vivo remains unclear, it generally is accepted that amyloid precursor protein (APP) is processed sequentially by several proteolytic events. Cleavage of the full-length precursor by alpha -secretase creates APPalpha sec, which is released into the medium, leaving behind a short membrane-bound C-terminal fragment (alpha CTF). Less frequently, the holoprotein is cleaved at a slightly more N-terminal site, generating beta CTF and APPbeta sec. APP CTFs can be processed further by gamma -secretase. This second cleavage event occurs within the membrane region of the C-terminal stumps and requires the multi-transmembrane-spanning proteins presenilin 1 (PS1) or PS2. Cleavage at the gamma -site of beta CTF generates the 4 kDa fragment amyloid-beta (Abeta ), which represents a major component of amyloid plaques in Alzheimer's disease (AD). Additional cleavage of alpha CTF yields the nonamyloidogenic peptide p3 (for review, see De Strooper and Annaert, 2000).

Increasing evidence indicates a role for cholesterol in the metabolism of APP. Carriers of the ApoE4 allele of apolipoprotein E are predisposed to an earlier onset for developing AD (Corder et al., 1993), and a high cholesterol diet accelerates Abeta deposition in transgenic mice (Refolo et al., 2000). Moreover, suppression of cholesterol neosynthesis strongly reduces the formation of Abeta species in vivo and in vitro (Simons et al., 1998; Frears et al., 1999; Fassbender et al., 2001; Refolo et al., 2001). Low-density lipoprotein (LDL) receptor family members such as LRP contribute to the endocytosis of APP, suggesting a role for internalization processes in APP metabolism (Kounnas et al., 1995). A fraction of APP molecules, as well as its secretases, localizes to cholesterol-rich membrane subdomains (Bouillot et al., 1996; Riddell et al., 2001). Recent data showing that Abeta accumulation is associated with NPC1 function (Yamazaki et al., 2001) as well as a strong correlation of cholesterol ester (CE) levels with Abeta generation (Puglielli et al., 2001) indicate that APP processing may be linked to intracellular cholesterol distribution.

In this study we investigate the role of a pathway that mediates the transfer of internalized cholesterol from late endocytic organelles to a sterol-regulating pool in the endoplasmic reticulum (ER) on APP cleavage and PS localization. Mutations in the genes encoding for NPC1 protein or the lysosomal protein HE1 cause cholesterol and other lipids to accumulate in late endosomes and lysosomes, resulting in Niemann-Pick C disease (NPC; Carstea et al., 1997; Naureckiene et al., 2000). Cells mutant in NPC1 show a block in cholesterol esterification by ER resident acyl-coenzyme A:cholesterol acyltransferase (ACAT), suggesting that NPC1 is involved actively in cholesterol transport between late endocytic compartments and the ER (Liscum et al., 1989; Cruz et al., 2000). Class-2 amphiphiles such as U18666A or imipramine mimic NPC disease by inhibiting either NPC1 protein itself or an unknown factor along its pathway (Lange et al., 2000).

Here we provide evidence for a link among intracellular cholesterol transport, Abeta generation, and PS localization. We show that the retention of cholesterol in late endosomal/lysosomal compartments is associated with major alterations in APP processing, inversely affecting beta - and gamma -secretase cleavage. Surprisingly, this is accompanied by an accumulation of PS1 and PS2 in Rab7-positive vesicular compartments that are directly adjacent to cholesterol-laden late endosomes under conditions in which intracellular cholesterol transport is blocked. Our results indicate that the subcellular distribution of cholesterol is an important factor in regulating the proteolytic cleavage of APP and suggest the possibility of a cholesterol-dependent trafficking of PS.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Cell culture. SH-SY5Y cells and mouse fibroblasts were cultivated in DMEM/5% fetal calf serum (FCS). Mutant Chinese hamster ovary (CHO) cells were grown in Ham-F12/5% FCS. Rab7-GFP-transfected A431 cells were grown in DMEM/5% FCS. Rab7 protein was fused at its N terminus to the C terminus of GFP with the pEGFP-C3 vector provided by Clontech Laboratories (Cambridge, UK). Stable cell lines were selected and maintained in medium containing 0.5 mg/ml G418 (Sigma-Aldrich, Munich, Germany). For the time of exposure to 50 µg/ml LDL (Sigma-Aldrich) and 3 µg/ml U18666A [3-beta -[2-(diethylamino)ethoxy]androst-5-en-17-one (Biomol, Hamburg, Germany); from a stock solution in ethanol stored at -20°C for <3 months] or 80 µM imipramine (Sigma-Aldrich), the FCS levels were increased to 10% to stimulate cholesterol internalization (Tabas et al., 1988).

Preparation of primary hippocampal neurons from 17-d-old fetal rats was performed as described previously (Goslin and Banker, 1991). Neurons were plated on poly-L-lysine-coated plastic dishes (Nunc, Dannstadt, Germany) or on poly-L-lysine-coated glass coverslips and cultivated under serum-free conditions in MEM containing N2 and B27 supplements (Invitrogen, San Diego, CA). E14 mixed cortical neurons were prepared and cultivated by following the same protocol, with cerebral cortices used instead of hippocampi. Hippocampal neurons were maintained in culture for 12-15 d; cortical neurons were used after 7-10 d in culture.

Antibodies and fluorescent dyes. The following primary antibodies have been described previously: polyclonal anti-PS1 N-terminal fragment (NTF) antibody 95.23 (Culvenor et al., 1997), monoclonal anti-v-ATPase antibody Osw2 (Papini et al., 1996), monoclonal 6C4-antibody to lysobisphosphatidic acid (LBPA; Kobayashi et al., 1998), monoclonal anti-COP-I antibody CM1A10 (Scales et al., 1997), and monoclonal antibody W02 directed to residues 4-10 of human Abeta (Jensen et al., 2000). G2-10 and G2-11 are monoclonal antibodies specific for the C-terminal residues of Abeta 40 and Abeta 42, respectively (Ida et al., 1996). Polyclonal antibody 29414 against PS1 CTF was provided by C. Elle (Center for Molecular Biology, University of Heidelberg, Germany). Oil red O (Sigma-Aldrich) was a gift from J. McLauchlan (MRC Virology Unit, University of Glasgow, UK). Monoclonal anti-calnexin and monoclonal anti-BiP/GRP78 antibodies were from Transduction Laboratories (BD Biosciences, Heidelberg, Germany), monoclonal anti-PS1-loop antibody was from Chemicon (Hofheim, Germany), and polyclonal PS2 antibody was from New England Biolabs (Frankfurt, Germany). For the simultaneous detection of cholesterol, primary antibodies were dissolved in 125 µg/ml filipin (Sigma-Aldrich). Mouse anti-rabbit and rabbit anti-mouse IgG (Alexa-488- or Alexa-568-conjugated) secondary antibodies were from Molecular Probes (Leiden, Netherlands). Horseradish peroxidase-conjugated rabbit anti-mouse or goat anti-rabbit secondary antibodies were from Dako A/S (Glostrup, Denmark).

Immunofluorescence, confocal microscopy, and image processing. Fully polarized hippocampal neurons, SH-SY5Y cells, mutant CHO cells, or A431 cells were incubated with 50 µg/ml LDL in the presence or absence of 0.75 or 3 µg/ml U18666A for 24 hr. Immunofluorescence labeling was performed according to the standard procedures; cells grown on glass coverslips were fixed in 3% paraformaldehyde for 10 min at 4°C and permeabilized with either 0.03% saponin (4°C for 1 min) or a brief dip into ice-cold methanol (-20°C). Alternatively, fixation and permeabilization were performed in ice-cold acetone (-20°C for 30 sec). Primary antibodies were centrifuged to exclude nonspecific aggregation, and the cells were incubated for 30 min at 4°C. After incubation with Alexa-conjugated secondary antibodies the cells were mounted in Mowiol (Calbiochem-Novabiochem, Bad Soden, Germany).

Samples were viewed with a Zeiss LSM 510 confocal microscope (Carl Zeiss, Oberkochen, Germany). Images were acquired with a 63× or 100× Plan-Apochromat III differential interference contrast objective (Carl Zeiss). Pinhole settings were ~1 airy unit for all images except for the detection of filipin (2-3 airy units). Fluorescent dyes were imaged sequentially in frame interlace mode to eliminate cross-talk between the channels. Images were sampled accordingly to satisfy the Nyquist criteria for all dimensions and were processed further with Adobe Photoshop (Mountainview, CA).

Lipid extraction and analysis. Fresh human LDL was mixed with 4[14C]cholesterol (Amersham Pharmacia Biotech, Braunschweig, Germany) in ethanol (final concentration < 0.1%) and dissolved in labeling medium to a final concentration of 50 µg/ml and a total 14C activity of 0.5 µCi/ml. Cells exposed to U18666A or imipramine and the controls were incubated for 2-24 hr at 37°C, 5% CO2. With the removal of the medium the cells were washed twice with PBS, and the lipids were extracted with hexane/isopropanol (3:2) for 30 min at 4°C. Solvent was evaporated under a gentle N2 stream; dried lipids were resolved in a small aliquot of hexane/isopropanol and subjected to unidimensional thin-layer chromatography (TLC) on general purpose silica gel plates (Sigma-Aldrich) in toluene/ethylacetate (2:1). Quantitative analysis of cholesterol ester formation and internalization of 14C-cholesterol were performed after film exposure of TLC plates and densitometric scanning with MacBAS 2 software. For neuronal cells, equal protein levels were checked by the extraction of proteins from cellular debris with 1N NaOH for 10 min at room temperature, followed by quantification with Coomassie blue protein assay (Pierce, Bezons, France).

Virus infection, immunoprecipitation, and quantitative Western blotting. Recombinant Semliki Forest virus (SFV) encoding human APP695 was prepared and applied as described previously (Tienari et al., 1996). After 8 hr of exposure to 50 µg/ml LDL and U18666A or ethanol as a solvent control (final concentration, <0.1%), conditioned media were collected and total cellular extracts were prepared with lysis buffer consisting of 1% NP-40, 1% Triton X-100, 0.2% SDS, and 5 mM EDTA supplemented with Complete protease inhibitor cocktail (Roche, Mannheim, Germany). SH-SY5Y cells overexpressing SP-C99 (Dyrks et al., 1993) were incubated with LDL and 3 µg/ml U18666A for 24 hr and processed for immunoprecipitation by a similar protocol. Samples were immunoprecipitated with monoclonal antibodies W02 (1 µg/ml), G2-10 (2 µg/ml), or G2-11 (4 µg/ml). For the determination of Abeta species, Western blot detection of immunoprecipitates was performed according to Ida et al. (1996). Standard Abeta solutions at different concentrations were used for calibration. Western blotting from neuronal lysates was performed with anti-PS1 antibody 95.23 (diluted 1:10,000 in PBS) or monoclonal anti-calnexin antibody (diluted 1:1000 in PBS).


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Inhibition of cholesterol trafficking in neuronal cells expressing full-length APP decreases proteolytic processing by beta -secretase

To elucidate the cellular mechanisms that connect cholesterol and Abeta generation, we investigated how alterations in intracellular cholesterol distribution might affect APP processing. In peripheral cells the transport of LDL-derived cholesterol to the ER can be inhibited by class-2 amphiphiles (Lange et al., 2000). Because cholesterol homeostasis in brain differs from peripheral tissue (Lütjohann et al., 1996), we first analyzed the transport of internalized cholesterol in neuronal cells by measuring its esterification by ER resident ACAT (Pentchev et al., 1987). SH-SY5Y neuroblastoma cells or fully polarized rat cortical neurons were incubated with LDL enriched in 14C-cholesterol in the presence or absence of U18666A or imipramine, and 14C-cholesterol ester formation was quantified. SH-SY5Y cells showed a reduction in cholesterol esterification by >80% with U18666A treatment and by >40% with exposure to imipramine at all time points that were investigated (Fig. 1A). Cholesterol ester levels in primary neurons decreased by ~60% (39.1% of control; n = 3; p < 0.05) (Fig. 1B) with exposure to U18666A. In contrast, cellular 14C-cholesterol load was not changed significantly, showing that the diminished esterification did not result from a disruption of cholesterol internalization. These results clearly show that cholesterol ester generation from internalized cholesterol takes place in cultured neurons and that these cells, as known from other cell types, show a marked inhibition of cholesterol transfer to metabolizing compartments in response to amphiphiles.



View larger version (47K):
[in this window]
[in a new window]
  		Figure 1.   Class 2 amphiphiles inhibit intracellular cholesterol transport and decrease beta -cleavage of APP in neuronal cells. SH-SY5Y cells (A) or mature rat cortical neurons in culture (B) were labeled with 14C-cholesterol in LDL for 2-12 hr (A) or 24 hr (B). 14C-cholesterol ester formation in cells incubated in the presence or absence of 3 µg/ml (for neuroblastoma cells) or 0.75 µg/ml (for primary neurons) U18666A or 80 µM imipramine was monitored by the extraction of lipids and subsequent TLC. Depicted are densitometric quantifications of 14C-cholesterol ester signal intensities as a percentage of the total 14C activity per lane (means from three experiments). CE, Cholesterol ester; Chol, cholesterol. C, SFV-infected mature rat cortical neurons were incubated for 8 hr with LDL at different concentrations of U18666A. Conditioned medium was immunoprecipitated with W02, followed by Western blot detection with W02. Immunoprecipitations of conditioned media from neurons exposed to LDL and either 0.75 µg/ml U18666A (+) or not (-) with antibodies G2-10 or G2-11 were detected with G2-10 to visualize secretory Abeta 40 and p3 or with W02 for the detection of secretory Abeta 42, respectively. D, Western blot of respective neuronal lysates with W02 (after W02 immunoprecipitation), anti-calnexin antibody, or antibody 95.23 against PS1 NTF. C, D, Quantifications of intracellular (ic) and secreted (sec) APP, beta CTF, and overall Abeta levels (n = 4-7 experiments). Depicted are ratios of signal intensities from U18666A- or imipramine-treated versus untreated primary cortical neurons or SH-SY5Y cells. Error bars indicate 1 SD.

We then investigated the effect of amphiphile-induced inhibition of cholesterol transport on APP processing in neuronal cells. Primary cultures of mixed cortical neurons were infected with recombinant SFV encoding for full-length human APP695. This expression system has been used widely to study sorting and processing of APP in neuronal cells and did not affect neuronal viability within the duration of our experiments (Tienari et al., 1996; De Strooper et al., 1998; Skovronsky et al., 1998). Infected neurons were exposed for 8 hr to LDL in the presence or absence of U18666A. As shown in Figure 1C, the application of U18666A to cortical neurons in culture resulted in a dose-dependent reduction in Abeta secretion. In contrast, the secretion of APP was reduced only slightly, arguing that diminished Abeta levels in the medium did not result from a general disruption of protein secretion. At concentrations of 0.75 µg of U18666A per milliliter of culture medium the levels of secretory Abeta decreased by ~50%, whereas APP levels remained essentially unaffected [0.491 ± 0.094, n = 4, p < 0.01 for secreted Abeta (Abeta sec); 0.958 ± 0.08 for secretory APP (APPsec)]. These observations were independent of the expression system or inhibiting drug, because similar effects could be obtained for SH-SY5Y cells stably expressing APP695 (0.633 ± 0.116, n = 5, p < 0.01 for Abeta sec; 1.009 ± 0.085 for APPic) as well as exposure of primary neurons to imipramine (0.661 ± 0.124, n = 7, p < 0.001 for Abeta sec; 0.98 ± 0.139 for APPic). A diminished secretion was prominent for both Abeta 40 and Abeta 42, indicating that none of the major gamma -secretase activities was perturbed in favor of the other. Reduced secretion of Abeta could not be explained by an increase in the alpha -secretory cleavage pathway of APP (Kojro et al., 2001), because we did not observe a compensatory upregulation of p3 levels.

Regardless of the treatment, levels of intracellular APP, calnexin, or PS1 fragments in neuronal lysates were unperturbed (Fig. 1D). However, we found remarkably less beta CTF with exposure to U18666A. Quantification revealed a decrease in beta CTF levels to an extent almost similar to intracellular Abeta levels in rat primary neurons [0.524 ± 0.203, n = 4, p < 0.05 for beta CTF; 0.486 ± 0.195 for intracellular Abeta (Abeta ic); 0.96 ± 0.244 for intracellular APP (APPic)] and human SH-SY5Y cells exposed to U18666A (0.723 ± 0.163, n = 3, p < 0.05 for beta CTF; 0.64 ± 0.304 for Abeta ic; 1.052 ± 0.053 for APPic). This effect was not specific for U18666A but also could be found in primary neurons exposed to imipramine (0.848 ± 0.1, n = 7, p < 0.01 for beta CTF; 0.755 ± 0.169 for Abeta ic; 0.991 ± 0.148 for APPic). Taken together, these results show that Abeta secretion and generation are reduced in neuronal cells inhibited in intracellular cholesterol transport. The similar decrease in Abeta and beta CTF levels indicates that this effect is attributable to a reduction in beta - rather than gamma -cleavage of full-length APP.

Inhibition of cholesterol transport increases gamma -secretase cleavage in neuronal cells expressing APP C-terminal fragment SP-C99

We now were interested in the specific effects that retention of cholesterol in late endosomal/lysosomal compartments might have on gamma -secretase activity. Cleavage by gamma -secretase depends on the previous production of APP beta CTF, which is generated by beta -secretase. Therefore, the inhibition of beta -secretase may conceal effects on gamma -secretase activity. The use of a truncated form of APP, SP-C99, instead of the full-length molecule, which acts as an immediate precursor for Abeta and as a direct substrate for gamma -secretase, allows for an isolated assessment of gamma -secretase activity and obviates beta -secretase cleavage for Abeta generation (Dyrks et al., 1993). beta CTF-like constructs have been shown previously as suitable models for studying gamma -cleavage in the absence of beta -cleavage (Xia et al., 2000).

We stably transfected SH-SY5Y cells with SP-C99 and exposed these cells to LDL-enriched culture medium in the presence or absence of 3 µg/ml U18666A. Western blot detection showed that levels of endogenously synthesized secretory human APP (APPsec) in conditioned medium from U18666A-treated cells primarily were unaffected compared with controls. Surprisingly, however, secretory and intracellular Abeta levels were elevated markedly (1.56 ± 0.221, n = 5, p < 0.01 for Abeta sec; 1.715 ± 0.172, n = 5, p < 0.0005 for Abeta ic) (Fig. 2A,B). In contrast, no major changes were found for secretory or intracellular endogenous APP (1.155 ± 0.134 for APPsec; 0.969 ± 0.074 for APPic). Similarly, treatment did not induce differences in C99 levels, the substrate for gamma -secretase after cotranslational cleavage of the signal peptide from SP-C99 (1.059 ± 0.118 for C99). These results indicate a highly significant increase of Abeta in neuroblastoma cells exposed to U18666A, indicating a strong upregulation of gamma -secretase activity in response to an altered subcellular cholesterol distribution.



View larger version (27K):
[in this window]
[in a new window]
  		Figure 2.   U18666A increases intracellular and secretory Abeta levels in SP-C99-transfected SH-SY5Y cells. Human SH-SY5Y neuroblastoma cells stably transfected with APP C-terminal fragment SP-C99 were incubated for 24 hr with 50 µg/ml LDL in the presence (+) or absence (-) of 3 µg/ml U18666A. Conditioned medium (A) and cell lysates (B) were immunoprecipitated with antibody W02, followed by Western blot detection with W02. Graphs show quantification of intracellular (ic) and secreted (sec) endogenous APP, C99, and overall Abeta levels (n = 5 experiments). Depicted are ratios of signal intensities from U18666A-treated versus untreated cells. Error bars indicate 1 SD. C, Medium and lysates of SH-SY5Y cells were immunoprecipitated with antibodies G2-10 and G2-11 specific for Abeta 40 and Abeta 42, respectively, and were detected with W02. Western blots with W02 show effects of U18666A treatment on secretory and intracellular Abeta species compared with C99.

Because of this strong enlargement of overall intracellular and secreted Abeta pools, we were interested in which of the major Abeta species might contribute to this effect. We found a remarkable increase in both Abeta 40 and Abeta 42 in cells exposed to U18666A compared with controls (Fig. 2C). This increase was prominent for secretory as well as for intracellular forms of both Abeta species, whereas no significant change could be found in the Abeta 40/Abeta 42 ratio.

Inhibition of cholesterol trafficking leads to an accumulation of presenilin1 in vesicular organelles associated with late endosomal/lysosomal compartments

Given this strong increase in the gamma -secretase product Abeta with the inhibition of intracellular cholesterol transport, we were interested in whether this effect might correlate with changes in proteins involved in gamma -secretase cleavage. In view of the role for PS in APP processing, we speculated that a stimulation of gamma -cleavage might correlate with an altered subcellular distribution of PS1 (De Strooper and Annaert, 2001). PS1 has been localized to a number of different subcellular compartments, depending on cell type and methods used for its detection. In neuronal cells the majority of PS1 was proposed to reside in the ER and the ER-Golgi intermediate compartment (Annaert et al., 1999). To investigate whether PS1 is affected by alterations in intracellular cholesterol distribution, we exposed SH-SY5Y neuroblastoma cells to U18666A, and we determined PS1 distribution by indirect immunofluorescence and confocal microscopy.

As expected for neuroblastoma cells (Kovacs et al., 1996; Culvenor et al., 1997) and regardless of the presence of LDL, PS1 in untreated and LDL-exposed cells showed a concentration in perinuclear and membranous organelles, although minor signals also were found at the plasma membrane and in vesicular compartments (Fig. 3A). Human vacuolar ATPase as a marker for late endosomes and lysosomes was spread in small vesicular structures throughout the cytosol (Fig. 3B), showing no major colocalization with filipin (Fig. 3C,D), which allows for visualization of cellular cholesterol (Neufeld et al., 1999). However, when cholesterol transport was inhibited by U18666A, v-ATPase-positive vesicles were enlarged and now retained the major pool of cellular cholesterol (Fig. 3F,G). Surprisingly, under these conditions a large fraction of PS1 signal could be seen in vesicular structures that showed a remarkable overlap with enlarged v-ATPase and filipin-positive vesicles (Fig. 3E-H). This vesicular staining pattern for PS1 in U18666A-treated SH-SY5Y cells was independent of the antibody that was used. Results were identical with a polyclonal antibody directed to the cytosolic loop region of PS1 CTF, and preimmunoabsorption of antibody 95.23 with PS1 NTF1-20 synthetic peptide abolished signals in both treated and untreated cells (data not shown).



View larger version (79K):
[in this window]
[in a new window]
  		Figure 3.   Inhibiting intracellular cholesterol transport induces an accumulation of PS1 in vesicular compartments associated with late endosomes and lysosomes. Human SH-SY5Y neuroblastoma cells were incubated for 24 hr with 50 µg/ml LDL in the presence (E-H) or absence (A-D) of 3 µg/ml U18666A. After fixation in paraformaldehyde the cells were triple labeled with polyclonal PS1 antibody 95.23 (A, E; green fluorescence), monoclonal antibody Osw2 to v-ATPase as a late endosomal/lysosomal marker (B, F; red fluorescence), and filipin for the detection of cellular cholesterol (C, G; blue fluorescence). Parental CHO-25RA cells (with regular sterol distribution) and CHO-CT43 cells (expressing a nonfunctional NPC1 protein) were incubated with 50 µg/ml LDL for 24 hr, fixed with paraformaldehyde, and triple labeled with PS1 antibody 95.23 (I, M), filipin (K, O), and the monoclonal antibody 6C4 against LBPA to visualize late endosomes (J, N; red fluorescence). D, H, L, P, Merged images. Arrows indicate selected regions positive for all three markers. Scale bars, 10 µm.

U18666A has been used widely to mimic a cholesterol-trafficking defect naturally occurring in Niemann-Pick C disease (Lange et al., 2000). As an alternative cellular model for NPC we used a mutant CHO cell line, CHO-CT43 (Cruz et al., 2000), which expresses a nonfunctional C-terminally truncated NPC1 protein and determined PS1 localization. After 24 hr of incubation in culture medium containing FCS and LDL, mutant CHO cells were fixed and stained for PS1 and cholesterol. As a late endosomal marker the monoclonal antibody 6C4 was used, which recognizes LBPA, a phospholipid highly enriched in internal membranes of late endosomes (Kobayashi et al., 1998). Like in U18666A-treated SH-SY5Y cells, PS1 frequently was associated with LBPA- and cholesterol-rich compartments in CHO-CT43 cells (Fig. 3M-P). In contrast, a predominantly ER-like staining pattern for PS1 was found in parental CHO-25RA cells, in which transport of internalized cholesterol to cholesterol-metabolizing compartments is active (Cruz et al., 2000) (Fig. 3I-L). These results from cholesterol-trafficking mutant stable cell lines show that effects of impaired cholesterol trafficking on PS1 localization are not attributable to potential short-term disturbances in membrane lipid composition by U18666A and suggest a correlation of cholesterol retention in late endosomal/lysosomal compartments and PS1 compartmentalization.

A more detailed analysis of U18666A-induced PS1-containing structures in SH-SY5Y cells revealed that PS1-containing compartments did not overlap completely with v-ATPase and presumably cholesterol-filled compartments but frequently appeared to surround these in a ring-like manner (Fig. 4A-C). Organelles positive for NPC1 and Rab7 with a very similar morphology and involved in cholesterol sorting have been described in fibroblasts enriched in LDL-derived cholesterol (Neufeld et al., 1999; Zhang et al., 2001). We therefore made use of a human A431 cell line stably expressing Rab7-GFP (M. de Bernard, unpublished data) and performed coimmunolabeling with a monoclonal antibody directed to the cytosolic loop region of PS1 CTF. As shown in Figure 4D-F, U18666A-treated cells showed a prominent colocalization of Rab7 and PS1 in vesicular structures that were concentrated in perinuclear areas. Colocalization with polyclonal antibody against PS2 showed that under these conditions PS2 also localized to these compartments (Fig. 4G-I). However, these compartments were not identical with lipid storage droplets (Pol et al., 2001) visualized with the neutral lipid stain Oil red O (Fig. 4J-L). Instead, with a localization near to the nucleus and a ring-like morphology surrounding a central cavity reported previously (Neufeld et al., 1999; Zhang et al., 2001), our findings argue strongly for an accumulation of PS in vesicular compartments involved in intracellular cholesterol distribution.



View larger version (52K):
[in this window]
[in a new window]
  		Figure 4.   PS-containing compartments are positive for Rab7 and surround late endosomes in a ring-like manner. SH-SY5Y (A-C) or A431 cells (D-L) were incubated for 24 hr with 50 µg/ml LDL and 3 µg/ml U18666A. After fixation in paraformaldehyde the SH-SY5Y cells were stained against PS1 (A, C; green) and v-ATPase (B, C; red). Fixed A431 cells stably overexpressing Rab7-GFP (E, H, K; green) were labeled with a monoclonal PS1 antibody (D, F; red), polyclonal PS2 antibody (G, I; red), or Oil red O to visualize neutral lipids (J, L; red). C, F, I, L, Merged images. Scale bars, 8 µm. Arrows indicate selected vesicles positive for both markers. Insets show single sections from confocal stacks of random vesicular structures in cell bodies. Scale bars in insets, 1 µm.

PS1 and Abeta 42 colocalize in Rab7-positive vesicular compartments in primary hippocampal neurons

We next analyzed the effects of U18666A on primary hippocampal neurons in culture. Colabeling of the late endosomal marker LBPA and filipin at higher magnification showed a notable overlap (Fig. 5C,E), confirming LBPA-positive late endosomes as cholesterol-retaining organelles after treatment of the cells with amphiphiles (Zhang et al., 2001). In contrast, Rab7-positive organelles were associated spatially with, but clearly distinct from, late endosomes enriched in cholesterol (Fig. 5F,H). Aggregated Abeta had been described previously in Rab7-positive endosomal fractions in U18666A-treated peripheral cells (Yamazaki et al., 2001). Thus we tested whether PS1 and Abeta colocalized to the same vesicular compartments in hippocampal neurons. As shown in Figure 5G and like in peripheral cells, PS1 in U18666A-treated hippocampal neurons distributed to vesicular compartments most likely corresponding to Rab7-positive organelles. Under these conditions in a subset of neurons the predominant fraction of endogenous Abeta 42 localized to PS1-containing vesicular compartments (Fig. 5G-I), indicating a close relationship of cholesterol retention, PS1 distribution, and increased gamma -secretase activity.



View larger version (45K):
[in this window]
[in a new window]
  		Figure 5.   Rab7-containing compartments after U18666A exposure of hippocampal neurons are distinct from cholesterol-retaining late endosomes and retain Abeta 42 and PS1. Mature hippocampal neurons were incubated with LDL and U18666A for 24 hr, fixed, and stained with filipin (B, E; red) and either monoclonal antibody 6C4 against LBPA (A, C; green) or a polyclonal antibody against Rab7 (D, F; green). G, H, Coimmunostainings of 95.23 for PS1 and monoclonal antibody G2-11 to detect cellular Abeta 42. A-C and insets in D-I show areas in the cell body of a hippocampal neuron. C, Merged image from A, B. F, Merged image from D, E. I, Merged image from G, H. Arrows indicate selected compartments. Scale bars, 4 µm.

To determine the specificity of PS1 accumulation with the exposure of neurons to U18666A, we performed coimmunolocalization with markers for different subcellular compartments. beta '-COP as a component of COP-I coats and parental Golgi membranes was largely excluded from PS1 or cholesterol-containing organelles (Fig. 6A-D). Similarly, no spatial correlation to filipin-positive compartments could be found for ER resident BiP/GRP78 (Fig. 6E-H), suggesting that an accumulation in vesicular compartments is not a general response of ER proteins after preventing delivery of cholesterol to the ER. Surprisingly, however, when we investigated the localization of ER protein calnexin in response to U18666A (Fig. 6J), a fraction of calnexin became prominent in punctuate structures associated with PS1-positive and cholesterol-retaining compartments (Fig. 4D-F). Higher magnification suggested that calnexin and PS1 partially colocalized to identical vesicular organelles.



View larger version (51K):
[in this window]
[in a new window]
  		Figure 6.   PS1-bearing vesicular compartments in hippocampal neurons impaired in cholesterol transport exclude beta 'COP and BiP but retain calnexin. Fully polarized rat hippocampal neurons in culture were incubated with 50 µg/ml LDL and 0.75 µg/ml U18666A for 24 hr. Neurons were fixed and triple labeled with antibody 95.23 (A, E, I), filipin (C, G, K), and monoclonal antibodies against beta 'COP (B), BiP/GRP78 (F), or calnexin (J). D, H, L, Merged images. Bottom insets show selected regions of single sections in the cell body of the depicted neuron (top insets). Arrows indicate selected compartments. Scale bars, 3 µm.

Finally, we tested whether the effects of U18666A on cholesterol transport were attributable to potential direct effects on PS. Fibroblasts from PS1 knock-out and PS1/PS2 double knock-out mice (Armogida et al., 2001) were exposed to U18666A, and CE generation in treated and untreated cells was determined. As shown in Figure 7, CE formation from internalized cholesterol can occur regardless of PS1 expression. Furthermore, U18666A decreased CE generation to a similar degree in wild-type and knock-out cells. Correspondingly, retention of cholesterol in late endosomes with the blocking of cholesterol transport by U18666A was unchanged (data not shown). Together, these results suggest that, although PS1 expression is not essential for an efficient transfer of internalized cholesterol to metabolizing sites, PS1 localization in hippocampal neurons correlates highly with the intracellular distribution of cholesterol.



View larger version (31K):
[in this window]
[in a new window]
  		Figure 7.   U18666A decreases cholesterol ester formation independently of PS1 expression. Cultured mouse fibroblasts from wild-type (PS1+/+PS2+/+), PS1 single knock-out (PS1-/-PS2+/+), and PS1/PS2 double knock-out (PS1-/-PS2-/-) mice were labeled with 14C-cholesterol in LDL in the presence (+) or absence (-) of 3 µg/ml U18666A for 24 hr. Lipids were extracted and separated by TLC. Effects of U18666A on CE formation in treated cells at equal CE levels in untreated cells are shown.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

This study reports that the intracellular distribution of cholesterol has substantial effects on the subcellular localization of PS and the amyloidogenic processing of APP. Our results suggest that the compartmentalization of cholesterol in neurons may play an important role in how cholesterol alters Abeta generation. We determined the effects of intracellular cholesterol distribution on PS localization and APP cleavage by two means, first by using compounds that inhibit cholesterol transport from endocytic compartments to the ER and second by examining cells expressing mutant NPC1.

We describe a dose-dependent reduction in both secreted and cellular Abeta species in neurons and neuroblastoma cells exposed to cholesterol transport-inhibiting amphiphiles. For several reasons we propose that the reduced formation of Abeta is attributable to a reduced beta -cleavage of APP. First, beta CTF levels decrease to an almost similar extent as overall secreted and intracellular Abeta , and Abeta 40 and Abeta 42 both decrease to a similar degree. Second, levels in APPsec and p3 do not rise, indicating that alpha -secretase cleavage of APP was not increased. Our results confirm previous data showing a strong correlation of beta -secretase activity and cholesterol metabolism in neuronal cells (Simons et al., 1998).

There are several possible mechanisms for how changes in subcellular cholesterol distribution could alter the beta -secretase cleavage of APP. We cannot exclude indirect effects on APP processing caused by alterations in endosomal or TGN function (Pentchev et al., 1987) or consecutive regulatory mechanisms after decreased transport of sterols to the ER (DeBose-Boyd et al., 1999). However, intriguing possibilities argue for a more direct role of the intracellular cholesterol transport on Abeta production. For example, reinternalization of surface APP during Abeta generation may be affected by a decreased cholesterol content in the plasma membrane in response to cholesterol-depleting agents that also reduce cholesterol transport to the ER (Subtil et al., 1999; H. Runz and T. Hartmann, unpublished results). Because the beta -secretase BACE1 has been shown to localize to lipid rafts (Riddell et al., 2001) and NPC1 plays a role in raft dynamics (Lusa et al., 2001), retention of cholesterol in endosomal/lysosomal compartments might interfere directly with beta -secretase function. Our findings of a reduced beta -cleavage of APP after the inhibition of cholesterol transport to the ER also correspond to a recent study showing a strong correlation of Abeta production and cellular CE levels (Puglielli et al., 2001). Inhibition of ACAT was associated with a prominent reduction in Abeta generation, which resulted from an inhibition of all three major processing events of APP.

Unexpectedly and in contrast to what we observed for beta -secretase cleavage, we found a dramatic increase in gamma -secretase activity accompanied by higher levels of secreted and intracellular Abeta when the transfer of LDL-derived cholesterol from endocytic compartments to ACAT in the ER was inhibited. This increase was prominent in cells expressing the beta CTF analog SP-C99 but was concealed in cells expressing full-length APP, where an increased gamma -cleavage could not compensate for a reduction in beta -cleavage as the rate-limiting step in Abeta generation. We cannot rule out that the effects on gamma -secretase are attributable to downstream effects on ACAT itself or mechanisms important for CE formation. However, a direct influence of NPC1 function or the transport of free cholesterol or other lipids to the ER on APP cleavage cannot be excluded.

This is supported further by the fact that regardless of how cholesterol transport was inhibited, we found a prominent accumulation of PS in vesicular organelles positive for Rab7 and intimately associated, but not identical, with cholesterol-retaining late endosomes. During cholesterol transport from the plasma membrane to the ER vesicular compartments are involved that contain NPC1 protein and are associated spatially but that are distinct from endosomal/lysosomal compartments required for the initial uptake of lipoprotein-derived cholesterol (Neufeld et al., 1999). Whereas cholesterol-enriched late endosomes are positive for lysosomal hydrolases, LBPA, and endocytic fluorescent-labeled dyes, NPC1-containing structures exclude these markers but are enriched instead in Rab7 and certain glycolipids (Zhang et al., 2001). The NPC1 compartment was described as a membranous organelle often surrounding cholesterol-laden late endosomes in a ring-like manner that may have a role in cholesterol sorting and the rapid transport of material between the plasma membrane and the ER (Cruz et al., 2000; Ko et al., 2001). The colocalization of PS with Rab7 as well as an identical morphology of PS-containing structures in our experiments indicate that, on blocking intracellular cholesterol transport, PS accumulates in these vesicular organelles involved in cholesterol sorting.

The localization of PS in vesicular organelles was surprising, because convincing evidence from neuronal cells shows a steady-state localization of PS1 predominantly in the ER (Kovacs et al., 1996; Culvenor et al., 1997; Annaert et al., 1999). Internalization of lipoprotein-derived cholesterol by neurons was reported to be low (Lütjohann et al., 1996). Nevertheless, neurons express LDL receptor family members (Herz et al., 1988), NPC1 (Falk et al., 1999) and ACAT (Sakashita et al., 2000) and thus possess molecular equipment involved in the uptake and utilization of lipoprotein-derived cholesterol. Accordingly, in our experiments amphiphiles diminished esterification of LDL-derived cholesterol in SH-SY5Y cells and primary cortical neurons. The block in cholesterol transfer to ACAT-containing compartments was sufficient to induce a massive accumulation of cholesterol in late endosomes positive for LBPA but distinct from Rab7-containing organelles. These results indicate that the intracellular transport of internalized cholesterol in primary neurons essentially follows identical routes as in peripheral cells (Zhang et al., 2001). Correspondingly, PS1 localized to vesicular compartments in the cell bodies of hippocampal neurons. Most interestingly, we also could detect a large fraction of Abeta 42 in these compartments. These microscopic data from neuronal cells inhibited in intracellular cholesterol transport are in accordance with a study showing a significant accumulation of Abeta in both NPC1 mutant CHO cells and NPC mouse brain (Yamazaki et al., 2001). In addition to their results proposing a pool of aggregated Abeta 42 in cholesterol- and Rab7-containing gradient fractions, our data showing a colocalization of PS1 and Abeta 42 raise the possibility that under these conditions Abeta 42 is produced in vesicular compartments involved in neuronal cholesterol transport.

How might an inhibition of intracellular cholesterol transport induce a shift in PS distribution and an increased gamma -secretase activity? One possibility is that alterations in subcellular cholesterol distribution might induce changes in ER membrane composition that could alter ER stability (Orci et al., 1984) and favor a relocalization of ER proteins to compartments involved in cholesterol sorting. This might be a reason for the unexpected localization of a fraction of ER membrane protein calnexin to these organelles in hippocampal neurons. The accumulation of PS and presumably other factors in Rab7- and NPC1-bearing organelles also might favor the assembly of the active high-molecular-weight gamma -secretase complex, which might stimulate formation of Abeta in these compartments. Because the site for gamma -cleavage of beta CTF is within the membrane domain of APP, a unique lipid composition of PS- and NPC1-containing compartments might favor Abeta generation further.

Alternatively, the redistribution of PS to organelles involved in cholesterol trafficking might support a proposed ER export model for PS-dependent gamma -cleavage of APP (De Strooper and Annaert, 2001). Analogies between APP processing and sterol-dependent trafficking and proteolysis in the regulation of sterol homeostasis are intriguing. When ER membranes are depleted from cholesterol, the sterol response element binding protein (SREBP) cleavage-activating protein (SCAP) escorts SREBP to the Golgi, where Site-1 protease activates SREBP, which subsequently is cleaved by an intramembranous proteolytic event that is very similar to the gamma -cleavage of APP (DeBose-Boyd et al., 1999). Recent data from living cells demonstrate a close interaction of NPC1-bearing organelles and the ER (Ko et al., 2001), and a threshold concentration of cholesterol in the endosomal/lysosomal system was proposed to induce a shift in NPC1 localization from a diffuse membranous organelle to these compartments (Zhang et al., 2001).

In conclusion, our results show that the intracellular compartmentalization of cholesterol is an important factor in determining PS localization and the regulation of APP cleavage. Further experiments in additional cellular and in vivo models systems will be required to elucidate its potential physiological and pathological implications on APP processing. In view of recent clinical studies reporting a potential benefit of regulating cholesterol metabolism as a strategy for preventing the onset of AD symptoms (Jick et al., 2000; Wolozin et al., 2000), our findings may help to design therapeutic approaches to cholesterol-dependent cellular events associated with AD. In providing a plausible link between factors such as ApoE or LRP in the endocytic limb and subsequent cholesterol-regulating events in the ER where, under balanced conditions, the major pool of PS is localized and gamma -cleavage may occur, we propose the intracellular cholesterol transport as a potential crossroad in Abeta generation.


    FOOTNOTES

Received Nov. 5, 2001; revised Nov. 5, 2001; accepted Nov. 30, 2001.

This work was supported by the Deutsche Forschungsgemeinschaft. We thank the following individuals for providing antibodies and reagents: J. Culvenor, C. Elle, J. Gruenberg, M. Zerial, and J. McLauchlan. We also thank B. De Strooper for the gift of PS mutant fibroblasts, T. Y. Chang for providing mutant CHO cell lines, and D. Stephens and G. W. Rebeck for critically reading this manuscript.

Correspondence should be addressed to Tobias Hartmann and Heiko Runz, Center for Molecular Biology (ZMBH), University of Heidelberg, Im Neuenheimer Feld 282, 69120 Heidelberg, Germany. E-mail: tobias.hartmann{at}mail.zmbh.uni-heidelberg.de or hrunz{at}ix.urz.uni-heidelberg.de.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

  • Annaert WG, Levesque L, Craessaerts K, Dierinck I, Snellings G, Westaway D, St. George-Hyslop P, Cordell B, Fraser P, De Strooper B (1999) Presenilin 1 controls gamma -secretase processing of amyloid precursor protein in pre-Golgi compartments of hippocampal neurons. J Cell Biol 147:277-294[Abstract/Free Full Text].
  • Armogida M, Petit A, Vincent B, Scarzello S, Alves da Costa C, Checler F (2001) Endogenous beta -amyloid production in presenilin-deficient embryonic mouse fibroblasts. Nat Cell Biol 3:1030-1033[Web of Science][Medline].
  • Bouillot C, Prochiantz A, Rougon G, Allinquant B (1996) Axonal amyloid precursor protein expressed by neurons in vitro is present in a membrane fraction with caveolae-like properties. J Biol Chem 271:7640-7644[Abstract/Free Full Text].
  • Carstea ED, Morris JA, Coleman KG, Loftus SK, Zhang D, Cummings C, Gu J, Rosenfeld MA, Pavan WJ, Krizman DB, Nagle J, Polymeropoulos MH, Sturley SL, Ioannou YA, Higgins ME, Comly M, Cooney A, Brown A, Kaneski CR, Blanchette-Mackie EJ (1997) Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science 277:228-231[Abstract/Free Full Text].
  • Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Periak-Vance MA (1993) Gene dose of apolipoprotein type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-923[Abstract/Free Full Text].
  • Cruz JC, Sugii S, Yu C, Chang TY (2000) Role of Niemann-Pick type C1 protein in intracellular trafficking of low density lipoprotein-derived cholesterol. J Biol Chem 275:4013-4021[Abstract/Free Full Text].
  • Culvenor JG, Maher F, Evin G, Malchiodi-Albedi F, Cappai R, Underwood JR, Davis JB, Karran EH, Roberts GW, Beyreuther K, Masters CL (1997) Alzheimer's disease-associated presenilin 1 in neuronal cells: evidence for localization to the endoplasmic reticulum-Golgi intermediate compartment. J Neurosci Res 49:719-731[Web of Science][Medline].
  • DeBose-Boyd RA, Brown MS, Li WP, Nohturfft A, Goldstein JL, Espenshade PJ (1999) Transport-dependent proteolysis of SREBP: relocation of site-1 protease from Golgi to ER obviates the need for SREBP transport to Golgi. Cell 99:703-712[Web of Science][Medline].
  • De Strooper B, Annaert W (2000) Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci 113:1857-1870[Abstract].
  • De Strooper B, Annaert W (2001) Presenilins and the intramembrane proteolysis of proteins: facts and fiction. Nat Cell Biol 3:E221-E225[Web of Science][Medline].
  • De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391:387-390[Medline].
  • Dyrks T, Dyrks E, Monning U, Urmoneit B, Turner J, Beyreuther K (1993) Generation of beta A4 from the amyloid protein precursor and fragments thereof. FEBS Lett 335:89-93[Web of Science][Medline].
  • Falk T, Garver WS, Erickson EP, Wilson JM, Yool AJ (1999) Expression of Niemann-Pick type C transcript in rodent cerebellum in vivo and in vitro. Brain Res 839:49-57[Web of Science][Medline].
  • Fassbender K, Simons M, Bergmann C, Stroick M, Lütjohann D, Keller P, Runz H, Kühl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T (2001) Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 levels in vitro and in vivo. Proc Natl Acad Sci USA 98:5856-5861[Abstract/Free Full Text].
  • Frears ER, Stephens DJ, Walters CE, Davies H, Austin BM (1999) The role of cholesterol in the biosynthesis of beta -amyloid. NeuroReport 10:1699-1705[Web of Science][Medline].
  • Goslin K, Banker G (1991) Rat hippocampal neurons in low-density culture. In: Cultivating nerve cells (Banker G, Goslin K, eds), pp 251-281. Cambridge, MA: MIT.
  • Herz J, Hamann U, Rogne S, Mykelbost O, Gausepohl H, Stanley KK (1988) Surface location and high affinity for calcium of a 500 kD liver membrane protein related to the LDL receptor suggest a physiological role as lipoprotein receptor. EMBO J 7:4119-4127[Web of Science][Medline].
  • Ida N, Hartmann T, Pantel J, Schroeder J, Zerfass R, Foerstel H, Sandbrink R, Masters CL, Beyreuther K (1996) Analysis of heterogeneous beta A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem 271:22908-22914[Abstract/Free Full Text].
  • Jensen M, Hartmann T, Engvall B, Wang R, Uljon SN, Sennvik K, Naslund J, Muehlhauser F, Nordstedt C, Beyreuther K, Lannfelt L (2000) Quantification of Alzheimer amyloid beta -peptides ending at residues 40 and 42 by novel ELISA systems. Mol Med 6:291-302[Web of Science][Medline].
  • Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA (2000) Statins and the risk of dementia. Lancet 356:1627-1631[Web of Science][Medline].
  • Ko DC, Gordon MD, Jin JY, Scott MP (2001) Dynamic movements of organelles containing Niemann-Pick C1 protein: NPC1 involvement in late endocytic events. Mol Biol Cell 12:601-614[Abstract/Free Full Text].
  • Kobayashi T, Stang E, Fang KS, De Moerloose P, Parton RG, Gruenberg J (1998) A lipid associated with the anti-phospholipid syndrome regulates endosome structure and function. Nature 392:193-197[Medline].
  • Kojro E, Gimpl G, Lammich S, März W, Fahrenholz F (2001) Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM10. Proc Natl Acad Sci USA 98:5815-5820[Abstract/Free Full Text].
  • Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Tanzi RE, Hyman BT, Strickland DK (1995) LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta -amyloid precursor protein and mediates its degradation. Cell 82:331-340[Web of Science][Medline].
  • Kovacs DM, Fausett HJ, Page KJ, Kim TW, Moir RD, Merriam DE, Hollister RD, Hallmark OG, Mancini R, Felsenstein KM, Hyman BT, Tanzi RE, Wasco W (1996) Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nat Med 2:224-229[Web of Science][Medline].
  • Lange Y, Ye J, Rigney M, Steck T (2000) Cholesterol movement in Niemann-Pick type C cells and in cells treated with amphiphiles. J Biol Chem 275:17468-17475[Abstract/Free Full Text].
  • Liscum L, Ruggiero RM, Faust JR (1989) The intracellular transport of low-density lipoprotein-derived cholesterol is defective in Niemann-Pick type C fibroblasts. J Cell Biol 108:1625-1636[Abstract/Free Full Text].
  • Lusa S, Blom TS, Eskelinen EL, Kuismanen E, Mansson JE, Simons K, Ikonen E (2001) Depletion of rafts in late endocytic membranes is controlled by NPC1-dependent recycling of cholesterol to the plasma membrane. J Cell Sci 114:1893-1900[Abstract].
  • Lütjohann D, Breuer O, Ahlborg G, Nennesmo I, Siden A, Diczfalusy U, Bjorkhem I (1996) Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci USA 93:9799-9804[Abstract/Free Full Text].
  • Naureckiene S, Sleat DE, Lackland H, Fensom A, Vanier MT, Wattiaux R, Jadot M, Lobel P (2000) Identification of HE1 as the second gene of Niemann-Pick C disease. Science 290:2298-2301[Abstract/Free Full Text].
  • Neufeld EB, Wastney M, Patel S, Suresh S, Cooney AM, Dwyer NK, Roff CF, Ohno K, Morris JA, Carstea ED, Incardona JP, Strauss III JF, Vanier MT, Patterson MC, Brady RO, Pentchev PG, Blanchette-Mackie EJ (1999) The Niemann-Pick C1 protein resides in a vesicular compartment linked to retrograde transport of multiple lysosomal cargo. J Biol Chem 274:9627-9635[Abstract/Free Full Text].
  • Orci L, Brown MS, Goldstein JL, Garcia-Segura LM, Anderson G (1984) Increase in membrane cholesterol: a possible trigger for degradation of HMG-CoA reductase and crystalloid endoplasmic reticulum in UT-1 cells. Cell 36:835-845[Web of Science][Medline].
  • Papini E, Gottardi E, Satin B, de Bernard M, Massari P, Telford J, Rappuoli R, Sato SB, Montecucco C (1996) The vacuolar ATPase proton pump is present on intracellular vacuoles induced by Helicobacter pylori. J Med Microbiol 45:84-89[Abstract/Free Full Text].
  • Pentchev PG, Comly ME, Kruth HS, Tokoro T, Butler J, Sokol J, Filling-Katz M, Quirk JM, Marshall DC, Patel S, Vanier MT, Brady RO (1987) Group C Niemann-Pick disease: faulty regulation of lipoprotein uptake and cholesterol storage in cultured fibroblasts. FASEB J 1:40-45[Abstract].
  • Pol A, Luetterforst R, Lindsay M, Heino S, Ikonen E, Parton R (2001) A caveolin dominant negative mutant associates with lipid bodies and induces intracellular cholesterol imbalance. J Cell Biol 152:1057-1070[Abstract/Free Full Text].
  • Puglielli L, Konopka G, Pack-Chung E, MacKenzie Ingano LA, Berezovska O, Hyman BT, Chang TY, Tanzi RE, Kovacs DM (2001) Acyl-coenzyme A:cholesterol acyltransferase modulates the generation of the amyloid beta -peptide. Nat Cell Biol 3:905-912[Web of Science][Medline].
  • Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff KE, Pappolla MA (2000) Hypercholesteremia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7:321-331[Web of Science][Medline].
  • Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, Tint GS, Wang R, Mercken M, Petanceska SS, Duff KE (2001) A cholesterol-lowering drug reduces beta -amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 8:890-899[Web of Science][Medline].
  • Riddell DR, Christie G, Hussain I, Dingwall C (2001) Compartmentalization of beta -secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts. Curr Biol 11:1288-1293[Web of Science][Medline].
  • Sakashita N, Miyazaki A, Takeya M, Horiuchi S, Chang CCY, Chang TY, Takahashi K (2000) Localization of human acyl-CoA:cholesterol acyltransferase-1 in macrophages and in various tissues. Am J Pathol 156:227-236[Abstract/Free Full Text].
  • Scales SJ, Pepperkok R, Kreis TE (1997) Visualization of ER-to-Golgi transport in living cells reveals a sequential mode of action for COPII and COPI. Cell 90:1137-1148[Web of Science][Medline].
  • Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K (1998) Cholesterol depletion inhibits the generation of beta -amyloid in hippocampal neurons. Proc Natl Acad Sci USA 95:6460-6464[Abstract/Free Full Text].
  • Skovronsky DM, Doms RW, Lee VM (1998) Detection of a novel intraneuronal pool of insoluble amyloid beta -protein that accumulates with time in culture. J Cell Biol 141:1031-1039[Abstract/Free Full Text].
  • Subtil A, Gaidarov I, Kobylarz K, Lampson MA, Keen JH, McGraw TE (1999) Acute cholesterol depletion inhibits clathrin-coated pit budding. Proc Natl Acad Sci USA 96:6775-6780[Abstract/Free Full Text].
  • Tabas I, Rosoff WJ, Boykow GC (1988) Acyl-coenzyme A:cholesterol acyltransferase in macrophages utilizes a cellular pool of cholesterol oxidase-accessible cholesterol as substrate. J Biol Chem 263:1266-1272[Abstract/Free Full Text].
  • Tienari PJ, De Strooper B, Ikonen E, Simons M, Weidemann A, Czech C, Hartmann T, Ida N, Multhaup G, Masters CL, van Leuven F, Beyreuther K, Dotti CG (1996) The beta -amyloid domain is essential for axonal sorting of amyloid precursor protein. EMBO J 15:5218-5229[Web of Science][Medline].
  • Wolozin B, Kellman W, Rousseau P, Celesia GG, Siegel G (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol 57:1439-1443[Abstract/Free Full Text].
  • Xia W, Ray WJ, Ostaszewski BL, Rahmati T, Kimberly WT, Wolfe MS, Zhang J, Goate AM, Selkoe DJ (2000) Presenilin complexes with the C-terminal fragments of amyloid precursor protein at the sites of amyloid beta -protein generation. Proc Natl Acad Sci USA 97:9299-9304[Abstract/Free Full Text].
  • Yamazaki T, Chang TY, Haass C, Ihara Y (2001) Accumulation and aggregation of amyloid beta -protein in late endosomes of Niemann-Pick type C cells. J Biol Chem 276:4454-4460[Abstract/Free Full Text].
  • Zhang M, Dwyer NK, Neufeld EB, Love DC, Cooney A, Comly M, Patel S, Watari H, Strauss III JF, Pentchev PG, Hanover JA, Blanchette-Mackie EJ (2001) Sterol-modulated glycolipid sorting occurs in Niemann-Pick C1 late endosomes. J Biol Chem 276:3417-3425[Abstract/Free Full Text].

Copyright © 2002 Society for Neuroscience  0270-6474/02/2251679-11$05.00/0


This article has been cited by other articles:


Home page
 J. Neurosci.Home page
D. Tampellini, N. Rahman, E. F. Gallo, Z. Huang, M. Dumont, E. Capetillo-Zarate, T. Ma, R. Zheng, B. Lu, D. M. Nanus, et al.
Synaptic Activity Reduces Intraneuronal A{beta}, Promotes APP Transport to Synapses, and Protects against A{beta}-Related Synaptic Alterations
J. Neurosci., August 5, 2009; 29(31): 9704 - 9713.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. Osenkowski, W. Ye, R. Wang, M. S. Wolfe, and D. J. Selkoe
Direct and Potent Regulation of {gamma}-Secretase by Its Lipid Microenvironment
J. Biol. Chem., August 15, 2008; 283(33): 22529 - 22540.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
M. Ewers, Z. Zhong, K. Burger, A. Wallin, K. Blennow, S. J. Teipel, Y. Shen, and H. Hampel
Increased CSF-BACE 1 activity is associated with ApoE-{varepsilon}4 genotype in subjects with mild cognitive impairment and Alzheimer's disease
Brain, May 1, 2008; 131(5): 1252 - 1258.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. O. W. Grimm, H. S. Grimm, I. Tomic, K. Beyreuther, T. Hartmann, and C. Bergmann
Independent Inhibition of Alzheimer Disease {beta}- and {gamma}-Secretase Cleavage by Lowered Cholesterol Levels
J. Biol. Chem., April 25, 2008; 283(17): 11302 - 11311.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
X. Chen, O. Ghribi, and J. D. Geiger
Rabbits fed cholesterol-enriched diets exhibit pathological features of inclusion body myositis
Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2008; 294(3): R829 - R835.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
R. A. Nixon
Autophagy, amyloidogenesis and Alzheimer disease
J. Cell Sci., December 1, 2007; 120(23): 4081 - 4091.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. Tampellini, J. Magrane, R. H. Takahashi, F. Li, M. T. Lin, C. G. Almeida, and G. K. Gouras
Internalized Antibodies to the Abeta Domain of APP Reduce Neuronal Abeta and Protect against Synaptic Alterations
J. Biol. Chem., June 29, 2007; 282(26): 18895 - 18906.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
G. H. Tansley, B. L. Burgess, M. T. Bryan, Y. Su, V. Hirsch-Reinshagen, J. Pearce, J. Y. Chan, A. Wilkinson, J. Evans, K. E. Naus, et al.
The cholesterol transporter ABCG1 modulates the subcellular distribution and proteolytic processing of {beta}-amyloid precursor protein
J. Lipid Res., May 1, 2007; 48(5): 1022 - 1034.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
W. S. Kim, A. S. Rahmanto, A. Kamili, K.-A. Rye, G. J. Guillemin, I. C. Gelissen, W. Jessup, A. F. Hill, and B. Garner
Role of ABCG1 and ABCA1 in Regulation of Neuronal Cholesterol Efflux to Apolipoprotein E Discs and Suppression of Amyloid-beta Peptide Generation
J. Biol. Chem., February 2, 2007; 282(5): 2851 - 2861.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
E. Ikonen
Mechanisms for cellular cholesterol transport: defects and human disease.
Physiol Rev, October 1, 2006; 86(4): 1237 - 1261.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. Rajendran, M. Honsho, T. R. Zahn, P. Keller, K. D. Geiger, P. Verkade, and K. Simons
Alzheimer's disease beta-amyloid peptides are released in association with exosomes
PNAS, July 25, 2006; 103(30): 11172 - 11177.
[Abstract] [Full Text] [PDF]

Home page
 Sci Aging Knowl EnvironHome page
B. A. Tate and P. M. Mathews
Targeting the Role of the Endosome in the Pathophysiology of Alzheimer's Disease: A Strategy for Treatment
Sci. Aging Knowl. Environ., June 28, 2006; 2006(10): re2 - re2.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
C. G. Almeida, R. H. Takahashi, and G. K. Gouras
Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system.
J. Neurosci., April 19, 2006; 26(16): 4277 - 4288.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
I. Jutras, A. Laplante, J. Boulais, S. Brunet, G. Thinakaran, and M. Desjardins
{gamma}-Secretase Is a Functional Component of Phagosomes
J. Biol. Chem., October 28, 2005; 280(43): 36310 - 36317.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
I. Y. Tamboli, K. Prager, E. Barth, M. Heneka, K. Sandhoff, and J. Walter
Inhibition of Glycosphingolipid Biosynthesis Reduces Secretion of the {beta}-Amyloid Precursor Protein and Amyloid {beta}-Peptide
J. Biol. Chem., July 29, 2005; 280(30): 28110 - 28117.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. L. Cole, A. Grudzien, I. O. Manhart, B. L. Kelly, H. Oakley, and R. Vassar
Statins Cause Intracellular Accumulation of Amyloid Precursor Protein, {beta}-Secretase-cleaved Fragments, and Amyloid {beta}-Peptide via an Isoprenoid-dependent Mechanism
J. Biol. Chem., May 13, 2005; 280(19): 18755 - 18770.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. J. Nelson and D. L. Alkon
Oxidation of Cholesterol by Amyloid Precursor Protein and {beta}-Amyloid Peptide
J. Biol. Chem., February 25, 2005; 280(8): 7377 - 7387.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
Y. Liu, L. Yang, K. Conde-Knape, D. Beher, M. S. Shearman, and N. S. Shachter
Fatty acids increase presenilin-1 levels and {gamma}-secretase activity in PSwt-1 cells
J. Lipid Res., December 1, 2004; 45(12): 2368 - 2376.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. S. Vetrivel, H. Cheng, W. Lin, T. Sakurai, T. Li, N. Nukina, P. C. Wong, H. Xu, and G. Thinakaran
Association of {gamma}-Secretase with Lipid Rafts in Post-Golgi and Endosome Membranes
J. Biol. Chem., October 22, 2004; 279(43): 44945 - 44954.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
K. M. Mann, F. E. Thorngate, Y. Katoh-Fukui, H. Hamanaka, D. L. Williams, S. Fujita, and B. T. Lamb
Independent effects of APOE on cholesterol metabolism and brain A{beta} levels in an Alzheimer disease mouse model
Hum. Mol. Genet., September 1, 2004; 13(17): 1959 - 1968.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
R. H. Takahashi, C. G. Almeida, P. F. Kearney, F. Yu, M. T. Lin, T. A. Milner, and G. K. Gouras
Oligomerization of Alzheimer's {beta}-Amyloid within Processes and Synapses of Cultured Neurons and Brain
J. Neurosci., April 7, 2004; 24(14): 3592 - 3599.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
R. A. Nixon
Niemann-Pick Type C Disease and Alzheimer's Disease: The APP-Endosome Connection Fattens Up
Am. J. Pathol., March 1, 2004; 164(3): 757 - 761.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
L.-W. Jin, I. Maezawa, I. Vincent, and T. Bird
Intracellular Accumulation of Amyloidogenic Fragments of Amyloid-{beta} Precursor Protein in Neurons with Niemann-Pick Type C Defects Is Associated with Endosomal Abnormalities
Am. J. Pathol., March 1, 2004; 164(3): 975 - 985.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. G. Cutler, J. Kelly, K. Storie, W. A. Pedersen, A. Tammara, K. Hatanpaa, J. C. Troncoso, and M. P. Mattson
Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease
PNAS, February 17, 2004; 101(7): 2070 - 2075.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
N. B. Chauhan
Membrane dynamics, cholesterol homeostasis, and Alzheimer's disease
J. Lipid Res., November 1, 2003; 44(11): 2019 - 2029.
[Abstract] [Full Text]

Home page
 J. Neurosci.Home page
M. Burns, K. Gaynor, V. Olm, M. Mercken, J. LaFrancois, L. Wang, P. M. Mathews, W. Noble, Y. Matsuoka, and K. Duff
Presenilin Redistribution Associated with Aberrant Cholesterol Transport Enhances {beta}-Amyloid Production In Vivo
J. Neurosci., July 2, 2003; 23(13): 5645 - 5649.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
U. Igbavboa, J. M. Pidcock, L. N. A. Johnson, T. M. Malo, A. E. Studniski, S. Yu, G. Y. Sun, and W. G. Wood
Cholesterol Distribution in the Golgi Complex of DITNC1 Astrocytes Is Differentially Altered by Fresh and Aged Amyloid beta -Peptide-(1-42)
J. Biol. Chem., May 2, 2003; 278(19): 17150 - 17157.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
R. H. Takahashi, T. A. Milner, F. Li, E. E. Nam, M. A. Edgar, H. Yamaguchi, M. F. Beal, H. Xu, P. Greengard, and G. K. Gouras
Intraneuronal Alzheimer A{beta}42 Accumulates in Multivesicular Bodies and Is Associated with Synaptic Pathology
Am. J. Pathol., November 1, 2002; 161(5): 1869 - 1879.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (109)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Runz, H.
Right arrow Articles by Hartmann, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Runz, H.
Right arrow Articles by Hartmann, T.

-
-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help
-
Copyright 2009 by Society for Neuroscience ONLINE ISSN: 1529-2401
-